Selpercatinib FoundationOne companion diagnostic - Foundation Medicine/Loxo oncology
Alternative Names: Selpercatinib FoundationOne®CDx - Foundation Medicine/Loxo oncologyLatest Information Update: 11 Oct 2023
At a glance
- Originator Foundation Medicine
- Developer Eli Lilly and Company; Foundation Medicine; Loxo Oncology
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Solid tumours
- Research Non-small cell lung cancer; Thyroid cancer
Most Recent Events
- 09 Oct 2023 Registered for Solid tumours (Diagnosis) in USA (unspecified route)
- 15 Feb 2022 Foundation Medicine and Eli Lilly and Company agree to develop selpercatinib FoundationOne companion diagnostic for cancer
- 14 Feb 2022 Early research in Non-small cell lung cancer (Metastatic disease) in USA (unspecified route)